Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mesenchymal stromal cells (University of Chile)
- Development stage
- Unknown
- Lead developer
- Universidad de los Andes
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
This investigational cell therapy consists of allogeneic mesenchymal stromal cells (MSCs) derived from the umbilical cord, delivered within a platelet-poor plasma (PPP) scaffold. Developed by the University of Chile, the treatment is specifically designed for patients with osteochondral lesions of the talus (LOC). It is administered as a biological augmentation to traditional arthroscopic debridement and microfracture surgery. The therapy aims to enhance the biological repair of ankle cartilage by promoting the formation of high-quality repair tissue, potentially superior to the fibrocartilage typically formed after standard microfracture procedures. It is currently being evaluated in a Phase 3 clinical trial (NCT03905824) to compare functional and radiological outcomes against standard surgical care.
- Other names
- Allogenic stromal mesenchymal cells derived from the umbilical cordumbilical cord-derived mesenchymal stem cellsUC-MSCAllogenic Stem Cells for Osteochondral Lesions of the Talus
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mesenchymal stromal cells (University of Chile).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stromal cells (University of Chile).